Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Patients with AML remain at risk of death after therapy. Our objective was to characterize patients with AML after three years in remission. 453 patients were documented to be alive and in remission 3 years after diagnosis, median follow-up was 7.2 years in this subgroup. 363 (80%) patients were alive at last follow-up, fifty-two (11%) relapsed, 40 died from relapse. Forty-seven (9%) died in remission. Among remission deaths, mutations in FLT3 (64% v 5%) and NPM1 (45% vs 20%) were common ( < 0.01); causes of death included: other cancers (26%), cardiovascular disease (6%), and graft-versus-host disease (6%). After 3 years in remission, the cumulative incidence of relapse was 8% (95%CI 5-11) and death was 11% (95%CI 8-14). Survival after 3 years in remission was similar to a matched general population cohort ( = 0.7). After 3 years in remission, most common causes of death were relapse, other cancer, or cardiovascular disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2025.2547984 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hematopathological profile of plasmacytoid dendritic cell proliferation associated with non-myeloid acute leukemia.
Cytometry B Clin Cytom
September 2025
Department of Hematopathology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Ch
Two types of plasmacytoid dendritic cell (pDC) proliferation disease are acknowledged so far by the 5th edition of the World Health Organization Classification of Haematolymphoid Tumors: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and mature pDC proliferation associated with myeloid neoplasms (MPDCP) in which pDC is part of the malignant clone. We aim to investigate pDC proliferation associated with non-myeloid acute leukemia (AL). A retrospective analysis of all cases admitted in our center with a diagnosis of non-myeloid AL from September 2020 to April 2023 was performed to select cases with pDCs greater than 2% of bone marrow by flow cytometry (FCM).
View Article and Find Full Text PDFMultiple Hematopoietic Stem Cell Transplantations in Pediatric Acute Myeloid Leukemia: Prognostic Significance of Remission and Severe Sinusoidal Obstruction Syndrome.
Pediatr Blood Cancer
September 2025
Acute Myeloid Leukemia Sub-Committee, Association of Childhood Leukemia Study (JACLS), Japan.
Background: Relapsed or refractory cases of pediatric acute myeloid leukemia (AML) have poor outcomes despite advancements in chemotherapy and hematopoietic stem cell transplantation (HSCT). While a second HSCT is often a salvage option, its outcomes vary widely, and prognostic factors remain unclear.
Objectives: This study aimed to evaluate outcomes and identify prognostic factors in pediatric patients with AML who underwent multiple HSCTs.
Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study.
Int J Hematol
September 2025
Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) has been shown to be effective in both adult and pediatric patients with acute promyelocytic leukemia (APL). Addition of ATO to conventional chemotherapy could lead to a reduction in the doses of cytotoxic agents, but the long-term safety of ATO is not fully understood, especially in children. The Japan Children's Cancer Group conducted a risk-stratified prospective study to investigate safety and efficacy of ATO in children with newly diagnosed APL by replacing all three intensification phases with ATO.
View Article and Find Full Text PDFDoes Time Matter From Diagnosis to Induction in Acute Myeloid Leukemia?
J Hematol
August 2025
Department of Hematology and Oncology, SUNY Upstate Medical University, Syracuse, NY, USA.
Background: While molecular and cytogenetic testing may change prognosis and guide treatment intensity for patients with acute myeloid leukemia (AML), timing from diagnosis to treatment (TDT) on the other hand may impact treatment outcomes and survival. These considerations are sometimes at odds with each other given that molecular studies can take up to 2 weeks to result.
Methods: A retrospective cohort analysis was conducted at SUNY Upstate University Hospital to examine the effect of TDT on complete remission (CR) and overall survival (OS).
Assessing the Impact of All-Trans Retinoic Acid (ATRA)- and Arsenic Trioxide (ATO)-Based Therapy in Pediatric Acute Promyelocytic Leukemia: A Single-Center Study.
Cureus
July 2025
Clinical Hematology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, IND.
Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by the t(15;17) translocation, leading to the PML-RARA fusion gene. While treatable, APL presents significant challenges, particularly in resource-constrained settings where delays in diagnosis and access to specialized care may impact outcomes. This study aims to describe the clinical presentation, treatment outcomes, and survival data for pediatric APL patients.
View Article and Find Full Text PDF